- Chromium III
- Chromium picolinate
- Niacin-bound chromium
- Chromium chloride
For Patients & Caregivers
Chromium may help to regulate blood glucose in some people, but the long-term effects are unknown. There is no clear evidence to show that chromium supplementation is effective for improving glucose metabolism, losing weight, or building muscle mass.
Chromium is an element required by the body in very small amounts (0.025 mg a day). Adequate amounts are usually obtained in the diet from foods such as American cheese, meat, fish, fruits, and whole grains. Based on laboratory experiments, scientists think that chromium is involved in maintaining adequate levels of glucose, fats, and insulin activity in the body. Chromium may interact with insulin receptors and enhance the effects of insulin on cells, including improved glucose uptake. In theory, this could help patients with type 2 diabetes.
Chromium is sometimes combined with GTF (Glucose Tolerance Factor) in over-the-counter products. GTF is a yeast extract that helps with glucose metabolism in laboratory studies, but this effect has not been confirmed in humans.
- To treat diabetes
Clinical trials produced conflicting results regarding chromium’s ability to lower blood glucose, cholesterol, and triglycerides.
- To improve muscle mass
Clinical trials do not support this use.
- To improve weight loss
Clinical trials do not support this use.
- To treat depression
Preliminary studies suggest some benefits with chromium supplementation for some types of depression and mood symptoms. More studies are needed.
In rare cases, liver toxicity has occurred.
- Kidney failure: In two patients who took chromium supplements to enhance weight loss.
- Red skin lesions: Accompanied with fever, swelling, and high white blood cell counts.
- Destruction of skeletal muscle: In one patient while taking chromium picolinate in addition to other dietary supplements. Therefore, whether chromium caused this condition is not clear.
- Low blood sugar: In a 29-year-old man with type 2 diabetes who took chromium supplements in addition to insulin.
For Healthcare Professionals
Chromium is a trace element that is necessary for glucose, insulin, and lipid metabolism in humans (1) (9). It is marketed as a dietary supplement for diabetes, weight loss, and to improve muscle mass. Trivalent chromium from yeast extract is sometimes referred to as glucose tolerance factor (GTF) in over-the-counter products.
Although most people consume adequate amounts through diet, chromium deficiency has been implicated in the development of diabetes (25). In vitro studies suggest that chromium produces beneficial modulatory effects under hyperglycemic conditions (26). Animal models also suggest antidiabetic (27) (28), antidepressant (29) (30) (31), and anxiolytic (32) properties.
In human studies, chromium supplementation with biotin may help to improve glycemic control in type 2 diabetes (T2D) (4) (5) (6). In a trial of patients with poorly controlled T2D, chromium supplementation had beneficial effects on glycemic control without affecting lipid profiles (33). Another study showed that chromium picolinate may increase satiety (15). However, many clinical studies failed to demonstrate a beneficial effect of chromium on glucose metabolism, weight loss, or muscle mass improvement (3) (7) (8) (9) (10) (11) (12) (13) (14).
Due to lack of clinical evidence, the FDA stated that chromium picolinate did not reduce the risk of insulin resistance or type-2 diabetes (16). More recently, the debate has continued, with one meta-analysis determining that overall, chromium monosupplementation significantly improved glycemic control, increased HDL-C levels, and reduced triglycerides (34), while another meta-analysis determined that chromium picolinate did not significantly affect A1C, and had no effect on fasting plasma glucose (35). Other clinicians posit that the mixed and modest effect sizes seen with chromium supplementation may reflect a greater glucoregulatory effect in complex patients with comorbid diabetes, depression, and binge eating (36). A large population study determined that those who consumed chromium-containing supplements had a reduced risk of T2D compared with those who did not, and warranted further study given the magnitude of exposure (37).
In other studies, chromium picolinate supplementation improved cerebral and memory function in elderly patients with early memory decline (17), produced antidepressant effects in patients with atypical depression (38), and improved mood symptoms in patients with premenstrual dysphoric disorder (39).
Chromium is poorly absorbed following oral administration, but salt forms such as chromium picolinate, niacin-bound chromium, and chromium chloride, appear to have better bioavailability. Other novel chromium compounds also have improved bioavailability (40) (41). Adverse effects are rare but can include renal failure (18) (19), rhabdomyolysis (20), liver damage (21), and dermatitis (22).
Chromium is an essential trace element involved with glucose and lipid metabolism, circulating insulin levels, and the peripheral activity of insulin (1). In vitro and in vivo studies suggest that chromium potentiates the activity of insulin (23) (42). This is thought to occur via enhanced intracellular tyrosine kinase activity that results from an interaction between chromium, low molecular weight chromium-binding substance, and activated cell surface insulin receptors (2).
In animal models of diabetes, chromium recovered beta cell functioning and alleviated macroangiopathy (27). It also augmented the insulin signaling pathway, dulled negative-regulators of insulin signaling, enhanced adenosine monophosphate-activated protein kinase (AMPK) activity to increase cellular glucose uptake, and attenuated oxidative stress (42). Chromium may also modulate peroxisome proliferator-activated receptor-gamma (PPAR-gamma), insulin receptor substrate (IRS-1), and nuclear factor-kappaB (NF-κB) proteins (28). Antidepressant effects occur via modified brain 5-hydroxytryptamine receptor (5-HT) function and increased serotonergic and noradrenergic functioning (30) (31). Additional mechanisms for antidepressant and anxiolytic effects include the lowering of plasma corticosterone levels via reversal of hypothalamic–pituitary–adrenal axis (HPA) axis overactivity (32). In humans, suggested antidepressant mechanisms include 5HT2A downregulation and increased insulin sensitivity (38).
Rare: Hepatic toxicity (21)
Renal failure: In a 33-year-old white woman who also presented with weight loss, anemia, thrombocytopenia, hemolysis, and liver dysfunction after chronic high doses of chromium picolinate to enhance weight loss (18) ; and in a 49-year-old female nurse who took chromium picolinate 600 mcg daily for 6 weeks for weight reduction (19).
Acute generalized exanthematous pustulosis: Characterized by erythematous lesions, fever, edema, leukocytosis, and eosinophilia (22).
Rhabdomyolysis: In a 24-year old patient taking chromium picolinate in addition to other dietary supplements (20).
Hypoglycemia: In a 29-year-old man with T2D after ingesting oral chromium 1000 mcg daily in addition to taking insulin (43).